As an increasing number of proteins are identified in genomics programs, the key to increasing efficiency and raising success rates will be to select the best candidates for clinical testing rather than pushing forward with every protein, or even the first protein identified in a given area.

For example, Human Genome Sciences Inc. last week published in Science the identification of B Lymphocyte Stimulator (BLyS), a member of the human